Get the Stockscreener App
9.04
0.11%
0.010
After Hours:
9.04
Nuvectis Pharma Inc stock is traded at $9.04, with a volume of 59,162.
It is up +0.11% in the last 24 hours and up +7.49% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$9.03
Open:
$8.93
24h Volume:
59,162
Relative Volume:
0.81
Market Cap:
$239.48M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-6.4113
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
+1.12%
1M Performance:
+7.49%
6M Performance:
+35.33%
1Y Performance:
+42.36%
1-Day Range:
$8.915
$9.125
1-Week Range:
$8.6288
$9.16
52-Week Range:
$5.55
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
9.04 | 239.22M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NVCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NVCT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
NVCT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[EFFECT] Nuvectis Pharma, Inc. SEC Filing - Stock Titan
(NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Nuvectis Pharma (NVCT) to Release Quarterly Earnings on Tuesday - Defense World
Is Nuvectis Pharma Inc. stock cheap at current valuationLayoff News & Smart Money Movement Alerts - mfd.ru
Is Nuvectis Pharma Inc. stock a smart buy before Fed meetingJuly 2025 Rallies & Free Accurate Trade Setup Notifications - mfd.ru
What are Nuvectis Pharma Inc.’s growth leversJuly 2025 Macro Moves & Entry Point Confirmation Alerts - mfd.ru
Nuvectis Pharma FY2026 EPS Estimate Cut by HC Wainwright - Defense World
Nuvectis Pharma Files $150 Million Mixed Shelf - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB) - The Globe and Mail
HC Wainwright Forecasts Weaker Earnings for Nuvectis Pharma - MarketBeat
HC Wainwright Comments on Nuvectis Pharma Q1 Earnings - Defense World
Can Nuvectis Pharma Inc. stock hit record highs againJuly 2025 PostEarnings & Entry Point Strategy Guides - mfd.ru
HC Wainwright Predicts Nuvectis Pharma Q1 Earnings - MarketBeat
Nuvectis Pharma, Inc. reports 2025 financial results and business highlights - marketscreener.com
Can Nuvectis Pharma Inc. be recession proof2025 Performance Recap & Low Volatility Stock Suggestions - mfd.ru
Nuvectis Pharma, Inc. SEC 10-K Report - TradingView
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - The Manila Times
Risk Analysis: Does Nuvectis Pharma Inc. have a competitive edgeEarnings Miss & Precise Entry and Exit Recommendations - baoquankhu1.vn
Does Nuvectis Pharma Inc. stock trade at a discount to peers2025 Macro Impact & Community Consensus Stock Picks - mfd.ru
Investment Report: Is Nuvectis Pharma Inc attractive for institutional investorsJuly 2025 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
(NVCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8%Should You Buy? - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy? - Defense World
Is Nuvectis Pharma Inc. stock a buy on dipsQuarterly Growth Report & Real-Time Volume Spike Alerts - bollywoodhelpline.com
Will Nuvectis Pharma Inc. stock outperform value stocksInsider Selling & Precise Trade Entry Recommendations - bollywoodhelpline.com
Investment Report: Will Nuvectis Pharma Inc outperform tech stocksGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Energy Moves: Is Nuvectis Pharma Inc stock a good pick for beginnersRisk Management & Low Drawdown Trading Techniques - baoquankhu1.vn
Take Profit: Can Nuvectis Pharma Inc maintain its current growth rateBreakout Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Spikes: Can Nuvectis Pharma Inc stock beat analyst upgradesJuly 2025 Recap & Real-Time Volume Spike Alerts - moha.gov.vn
What Wall Street predicts for Nuvectis Pharma Inc. stock price2025 Major Catalysts & Advanced Swing Trade Entry Plans - Улправда
We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st
Will Nuvectis Pharma Inc. stock benefit from commodity pricesSmall Cap Stock Opportunities & Grow Smarter With Pro-Level Research - Улправда
Why (NVCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - MSN
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5%Here's Why - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why - Defense World
Is Nuvectis Pharma Inc a good long term investmentEx-Dividend Date Alerts & High Return Trading Strategies - earlytimes.in
Why Nuvectis Pharma Inc. stock remains on buy listsFed Meeting & Growth Focused Stock Reports - Улправда
How rising interest rates impact Nuvectis Pharma Inc. stockEarnings Growth Summary & Verified Swing Trading Watchlists - DonanımHaber
Can Nuvectis Pharma Inc. stock beat analyst upgrades2025 Earnings Impact & Daily Growth Stock Investment Tips - DonanımHaber
Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Sentiment Report & Entry and Exit Point Strategies - DonanımHaber
Will Nuvectis Pharma Inc. stock maintain dividend yield2025 Risk Factors & Weekly Stock Breakout Alerts - DonanımHaber
Weekly Recap: Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Trend Summary & Capital Efficient Trade Techniques - bolumsonucanavari.com
Nuvectis Pharma announces initiation of Phase 1b study of NXP900 - MSN
Nuvectis Begins Phase 1b Study to Address Drug Resistance in Lung Cancer - socialunderground.co
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib By Investing.com - Investing.com Nigeria
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):